Aclaris Therapeutics, Inc. Quarterly Employee-related Liabilities, Current in USD from Q3 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Aclaris Therapeutics, Inc. quarterly Employee-related Liabilities, Current history and growth rate from Q3 2015 to Q3 2024.
  • Aclaris Therapeutics, Inc. Employee-related Liabilities, Current for the quarter ending September 30, 2024 was $2.6M, a 47.6% decline year-over-year.
Employee-related Liabilities, Current, Quarterly (USD)
Employee-related Liabilities, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $2.6M -$2.37M -47.6% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $2.14M -$1.77M -45.3% Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $1.69M -$940K -35.7% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $3.91M -$1.39M -26.2% Dec 31, 2023 10-Q 2024-11-06
Q3 2023 $4.97M +$1.14M +29.7% Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $3.91M +$1.02M +35.4% Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $2.63M +$450K +20.6% Mar 31, 2023 10-Q 2023-05-08
Q4 2022 $5.3M +$906K +20.6% Dec 31, 2022 10-K 2024-02-27
Q3 2022 $3.83M +$985K +34.6% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $2.89M +$963K +50.1% Jun 30, 2022 10-Q 2022-08-03
Q1 2022 $2.18M +$827K +60.9% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $4.39M +$418K +10.5% Dec 31, 2021 10-K 2023-02-23
Q3 2021 $2.85M +$329K +13.1% Sep 30, 2021 10-Q 2021-11-02
Q2 2021 $1.92M -$567K -22.8% Jun 30, 2021 10-Q 2021-08-05
Q1 2021 $1.36M -$62K -4.37% Mar 31, 2021 10-Q 2021-05-07
Q4 2020 $3.97M +$650K +19.6% Dec 31, 2020 10-K 2022-02-24
Q3 2020 $2.52M -$149K -5.59% Sep 30, 2020 10-Q 2020-11-04
Q2 2020 $2.49M -$1.17M -32% Jun 30, 2020 10-Q 2020-08-07
Q1 2020 $1.42M -$1.49M -51.3% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $3.32M -$1.63M -32.9% Dec 31, 2019 10-K 2021-02-25
Q3 2019 $2.67M -$1.55M -36.8% Sep 30, 2019 10-Q 2019-11-07
Q2 2019 $3.66M -$262K -6.68% Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $2.91M -$88K -2.93% Mar 31, 2019 10-Q 2019-05-08
Q4 2018 $4.95M +$1.94M +64.4% Dec 31, 2018 10-K 2020-02-25
Q3 2018 $4.22M +$2.32M +122% Sep 30, 2018 10-Q 2018-11-06
Q2 2018 $3.92M +$2.85M +265% Jun 30, 2018 10-Q 2018-08-03
Q1 2018 $3M +$2.48M +482% Mar 31, 2018 10-Q 2018-05-08
Q4 2017 $3.01M +$1.28M +73.8% Dec 31, 2017 10-K 2019-03-18
Q3 2017 $1.9M +$811K +74.5% Sep 30, 2017 10-Q 2017-11-07
Q2 2017 $1.07M +$375K +53.6% Jun 30, 2017 10-Q 2017-08-08
Q1 2017 $515K +$205K +66.1% Mar 31, 2017 10-Q 2017-05-09
Q4 2016 $1.73M Dec 31, 2016 10-K 2018-03-12
Q3 2016 $1.09M +$625K +135% Sep 30, 2016 10-Q 2016-11-03
Q2 2016 $699K Jun 30, 2016 10-Q 2016-08-11
Q1 2016 $310K Mar 31, 2016 10-Q 2016-05-11
Q3 2015 $463K Sep 30, 2015 10-Q/A 2015-12-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.